Cost considerations in the management of atrial fibrillation &ndash; impact of dronedarone | Zendy

Yaariv Khaykin | Zendy; Shamiss | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost considerations in the management of atrial fibrillation – impact of dronedarone

Author(s) -

Yaariv Khaykin,

Shamiss

Publication year - 2012

Publication title -

clinicoeconomics and outcomes research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.591

H-Index - 27

ISSN - 1178-6981

DOI - 10.2147/ceor.s16675

Subject(s) - dronedarone , medicine , atrial fibrillation , management of atrial fibrillation , cardiology , intensive care medicine , amiodarone

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is associated with significant morbidity and mortality. At the societal level, AF carries an enormous cost. Strategies aimed at reducing AF morbidity and mortality and containing the associated fiscal burden are of paramount importance. This review will discuss AF treatment strategies and economics, focusing on the impact of dronedarone, a novel antiarrhythmic agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research